Literature DB >> 15755967

Estrogen-receptor biology: continuing progress and therapeutic implications.

C Kent Osborne1, Rachel Schiff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15755967     DOI： 10.1200/JCO.2005.10.036

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  104 in total

1.  Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis.

Authors:  Evangelos Tsiambas; Stavros N Georgiannos; Nikolaos Salemis; Despoina Alexopoulou; Sofia Lambropoulou; Blerta Dimo; Ioannis Ioannidis; Christos Kravvaritis; Andreas Karameris; Efstratios Patsouris; Spyridon Dourakis
Journal:  Med Oncol       Date:  2010-05-11       Impact factor: 3.064

Review 2.  microRNAs and EMT in mammary cells and breast cancer.

Authors:  Josephine A Wright; Jennifer K Richer; Gregory J Goodall
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-25       Impact factor: 2.673

3.  Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action.

Authors:  Patricia Coutinho; Christopher Vega; Luminita H Pojoga; Alicia Rivera; Gregory N Prado; Tham M Yao; Gail Adler; Manuel Torres-Grajales; Enrique R Maldonado; Arelys Ramos-Rivera; Jonathan S Williams; Gordon Williams; Jose R Romero
Journal:  Endocrinology       Date:  2014-03-21       Impact factor: 4.736

4.  ERβ expression and breast cancer risk prediction for women with atypias.

Authors:  Tina J Hieken; Jodi M Carter; John R Hawse; Tanya L Hoskin; Melanie Bois; Marlene Frost; Lynn C Hartmann; Derek C Radisky; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

Review 5.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

6.  Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

Authors:  John M S Bartlett; Cassandra L Brookes; Tammy Robson; Cornelis J H van de Velde; Lucinda J Billingham; Fiona M Campbell; Margaret Grant; Annette Hasenburg; Elysée T M Hille; Charlene Kay; Dirk G Kieback; Hein Putter; Christos Markopoulos; Elma Meershoek-Klein Kranenbarg; Elizabeth A Mallon; Luc Dirix; Caroline Seynaeve; Daniel Rea
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

7.  Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.

Authors:  Ines Barone; Stefania Catalano; Luca Gelsomino; Stefania Marsico; Cinzia Giordano; Salvatore Panza; Daniela Bonofiglio; Gianluca Bossi; Kyle R Covington; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

8.  Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Authors:  Hannah M Linden; Brenda F Kurland; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; Georgiana K Ellis; Thomas J Lawton; Robert B Livingston; Philip H Petra; Jeanne M Link; Kenneth A Krohn; David A Mankoff
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

Review 9.  Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

Authors:  Andrea Milani; Elena Geuna; Gloria Mittica; Giorgio Valabrega
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 10.  Endocrine therapy of metastatic breast cancer.

Authors:  Laura Rodríguez Lajusticia; Miguel Martín Jiménez; Sara López-Tarruella Cobo
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.